21 CFR 211.22(c)
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.22(c): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR 211.22(c)?
- 3 DSRV articles cite 21 CFR 211.22(c). Enforcement cases behind them: Anthropic Managed Agents (July 2026 public beta) read against Purolea Cosmetics Lab FDA Warning Letter (April 2026); MCP 2026-07-28 release candidate; FDA Warning Letter to Purolea Cosmetics Lab (April 2026); FDA Warning Letter to Purolea Cosmetics Lab, April 2, 2026, CDER, CGMP/Adulterated/Unapproved New Drug. Inspection exposure across them: 3 high.
- What does DSRV recommend for 21 CFR 211.22(c)?
- From the newest article (Your Next 483 Observation Is Running on a Timer): Defining the QU boundary, validation basis, and change-control wrapper around autonomous agent actions is the firm's job, not the vendor's — settle it before a scheduled agent fires. DSRV is decision support, not legal advice; verify against the official source each article names.
- 6 min readHigh exposure
Your Next 483 Observation Is Running on a Timer
Anthropic's July 2026 Managed Agents release ships scheduled autonomous runs and authenticated enterprise access. Pharma quality teams that have approved these capabilities without a QU review checkpoint built into the workflow architecture are building toward a Purolea-pattern inspection finding.
- Case
- Anthropic Managed Agents (July 2026 public beta) read against Purolea Cosmetics Lab FDA Warning Letter (April 2026)
- DSRV take
- Defining the QU boundary, validation basis, and change-control wrapper around autonomous agent actions is the firm's job, not the vendor's — settle it before a scheduled agent fires.
- 5 min readHigh exposure
MCP Goes Stateless on July 28. For Pharma AI Teams, That Is a Change Control Event.
The MCP protocol's July 28 release candidate introduces six breaking changes and deprecates three core primitives. For pharma teams running MCP-enabled tools, the deadline is a validation checkpoint and a documentation obligation under FDA's AI-CGMP enforcement precedent.
- Case
- MCP 2026-07-28 release candidate; FDA Warning Letter to Purolea Cosmetics Lab (April 2026)
- DSRV take
- Treat the July 28 protocol change like any infrastructure update in a validated environment: inventory MCP-enabled tools, confirm vendor SDK migration, and document the change-control decision before the deadline.
- 7 min readHigh exposure
The AI Never Told Us: What FDA's First AI Warning Letter Really Means
A Michigan homeopathic drug manufacturer used AI agents to generate SOPs, specifications, and production records. FDA's April 2026 warning letter drew the enforcement line the industry had been watching for.
- Case
- FDA Warning Letter to Purolea Cosmetics Lab, April 2, 2026, CDER, CGMP/Adulterated/Unapproved New Drug.
- DSRV take
- FDA is not creating a new AI standard. It is applying the existing one. QU review of AI-generated GMP documents is mandatory. Purolea is now the primary enforcement reference.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR 211.22(c). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.